Robot maker · registered

Wandercraft

Corporate markethumanoidCurated record

Exoskeleton pioneer whose self-balancing bipedal control (from its Atalante X rehab exoskeleton and Eve personal exoskeleton) underpins Calvin-40, an AI-driven industrial humanoid for heavy load handling on assembly lines; Renault Group is its first commercial Calvin-40 customer and a Series D investor.

HeadquartersParis, FR

Founded2012

Corporate funding$146M

Team51-200

Deployments4

Open roles0

Company overview

Identity and operating footprint

Company typeRobot maker

Market segmentCorporate

StageSeries D

FoundersMatthieu Masselin, Nicolas Simon, Alexandre Boulanger, Jean-Louis Constanza

Regions servedEU, US

Countries deployedFR

Service footprintHQ Paris FR; US office in New York; Atalante X deployed in 100+ hospitals and rehabilitation centers across 15+ countries

Last reviewed2026-07-05

LinkedInView profile

Robot models

Specifications remain vendor-claimed

Machinehumanoid

Atalante X

Self-balancing medical exoskeleton for hospital rehabilitation training, FDA-cleared with extended indications
vendor-defined clinical rehabilitation exoskeleton
Claim source

Machinehumanoid

Calvin-40

Can lift up to ~40 kg (90 lb) several hundred times a day without rest
vendor-claimed repeated lift payload and duty cycle
Claim source
Designed for continuous use of 8 to 22 hours per day with a target fail rate < 1/1000
vendor-defined operational duty cycle and reliability target
Claim source

Machinehumanoid

Eve

First self-balancing personal exoskeleton, hands-free and usable without crutches (US clinical trial enrollment underway)
vendor-defined personal mobility exoskeleton
Claim source

Deployment log

Announced and cited only

Announced	Customer	Site	Country	Count	Evidence
2026-06-25	National Seating & Mobility (NSM)	CRT distribution partner / Eve exoskeleton launch	US	Not disclosed	Announcement
2025-11-25	Sapa	industrial manufacturing	FR	Not disclosed	Announcement
2025-07-09	Moody Neurorehabilitation Institute	neurorehabilitation	US	Not disclosed	Announcement
2025-06-06	Renault Group	automotive assembly plant (Douai)	FR	Not disclosed	Announcement

Funding history

Publicly announced rounds

2025-06-11$75M

Series D

AG2R LA MONDIALE, Bpifrance, Cemag Invest, LBO France, Martagon Capital, Mutuelles Impact (managed by XAnge), Quadrant Management, Renault Group, Teampact Ventures

Round source

2022-01-19$45M

Series C

Quadrant Management, Teampact Ventures

Round source

2018-01-01$4M

Grant

European Commission

Round source

2017-09-28$18M

Series B

Bpifrance, Cemag Invest, Idinvest Partners, LBO France, XAnge

Round source

2015-11-23$4M

Series A

LBO France

Round source

Investors on recordRenault GroupBpifranceQuadrant ManagementTeampact VenturesLBO France

Company timeline

Milestones and announcements

2026-03-10Renault announces plan to deploy 350 Calvin-40 humanoids across manufacturing facilities within 18 months; Douai plant already operational on tire handling tasksHumanoids Daily

2026-03-10Renault to Deploy 350 Wandercraft Calvin Humanoids in Industrial Speed Run ↗Humanoids Daily

2025-11-25Wandercraft and SAPA Announce Deployment Partnership to Implement and Scale Deployment of Calvin-40 ↗Humanoid Robotics Technology

2025-11-03FDA grants second indication extension for Atalante X covering high-level SCI (C4–L5) and multiple sclerosis; deployed 100+ rehab centers, 1M+ steps/monthGlobeNewswire

2025-11-03Wandercraft Gains Second FDA Indication Extension for Atalante X: covering high-level SCI and MS ↗GlobeNewswire

2025-06-11Raised $75M Series D led by Renault Group and Bpifrance for global Calvin-40 and Eve expansionWandercraft

2025-06-11Wandercraft announces Series D Round, bringing $75M in total funding secured ↗GlobeNewswire

2025-06-06Renault Group finalises a strategic partnership with Wandercraft ↗Renault Group Media

2024-02-13Atalante X receives second FDA clearance for spinal cord injury rehabilitation (T5–L5)GlobeNewswire

2024-02-13Wandercraft's self-balancing exoskeleton receives second FDA clearance for spinal cord injury rehabilitation ↗GlobeNewswire

2023-01-23Atalante X receives first FDA clearance (stroke/CVA rehabilitation)Newswire

2022-01-19Raised $45M Series C led by Quadrant Management for US expansion and Eve personal exoskeleton developmentTechCrunch